It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed semaglutide had a 50% higher risk of being diagnosed with a hair-loss condition compared to those prescribed Contrave. That risk was twice as high for women as for men.

Amy Schumer opened up about taking the weight loss drug Mounjaro after previously ‘horrible experience’ while on Wegovy. ‘Couldn’t handle it.’